GB 29 Tablet SR is a sustained-release formulation combining Methylcobalamin 1500 mcg and Pregabalin 75 mg, designed for the management of neuropathic pain and associated neurological disorders. Methylcobalamin, an active form of vitamin B12, plays a crucial role in nerve regeneration and repair by promoting myelin sheath synthesis and enhancing neuronal function. Pregabalin, a gamma-aminobutyric acid (GABA) analogue, exerts analgesic, anxiolytic, and anticonvulsant effects by modulating calcium channel activity in the central nervous system, thereby reducing neurotransmitter release and neuronal excitability. This combination is particularly effective in treating peripheral neuropathies, diabetic neuropathic pain, postherpetic neuralgia, and fibromyalgia. The sustained-release mechanism ensures a gradual and prolonged drug release, improving patient compliance and maintaining stable plasma concentrations. GB 29 Tablet SR should be administered as prescribed by a healthcare professional, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include dizziness, somnolence, gastrointestinal disturbances, and peripheral edema. Caution is advised in patients with renal impairment, and concomitant use with CNS depressants should be monitored closely. Overall, GB 29 Tablet SR offers a synergistic approach to neuropathic pain management by combining neurotrophic support with effective analgesia.